FDAnews
www.fdanews.com/articles/200869-sanofi-biond-biologics-partner-to-develop-cancer-drug

Sanofi, Biond Biologics Partner to Develop Cancer Drug

January 14, 2021

Israel-based Biond Biologics has signed a license agreement with Sanofi for the development and commercialization of BND-22, an investigational cancer treatment.

Biond will receive $125 million in cash up front and potentially more than $1 billion upon reaching development, regulatory and sales milestones, as well as royalty payments.

The company will lead an early-stage study of its antibody treatment as a single agent and in combination with approved cancer therapeutics. If the early research shows promise, Sanofi will take on the clinical development and commercialization responsibilities.

View today's stories